why choose us

First received: July 17, 2023

Clinical Trial: Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients with Various Solid Tumors

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Refractory Solid Tumor

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Non-Randomized, Single-Center, Investigator-initiated Phase II Trial to Determine the Efficacy and Safety of 177Lu-DOTA-EB-FAPI in Patients with Various End-stage Solid Tumors

Brief Summary: Increased fibroblast activation protein expression is positively correlated with the aggressiveness of cancer.Radiolabeled fibroblast activation protein inhibitor therapy, also known as radioligand therapy has become a novel treatment for patients with refractory cancer and disease progression after multiple-lines treatment.However, a major problem in the therapeutic use of 177Lu-DOTA-FAPI has been its short half-life and fast rate of clearance.This study was designed to investigate the efficacy and safety of…

Read more